SEP-380135 Clinical Trials (2026): 3 Studies for Schizophrenia & Bipolar Disorder
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
3 SEP-380135 clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 1 indication (including Schizophrenia & Bipolar Disorder) and 63 total planned enrollment. 1 SEP-380135 clinical trial is actively recruiting. Most recent activity: NCT07455084 (May 2026).
SEP-380135 clinical trials at a glance: phase × recruitment status
| Phase | completed | not yet recruiting | Total |
|---|---|---|---|
| P1 | 2 | 1 | 3 |
Recruiting SEP-380135 clinical trials (1)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT07455084 | A Study to Detect the Radioactivity of 14C-SEP-380135 in Urine and Feces in Healthy Male Adults | P1 | Schizophrenia | 8 | Mar 2026 |
All SEP-380135 trials (3)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT07455084 | A Study to Detect the Radioactivity of 14C-SEP-380135 in Urine and Feces in Healthy Male Adults | P1 | not yet recruiting | 8 | Otsuka Pharmaceutical Development & Commercialization, Inc. | Mar 2026 | |
| NCT07549581 | A Study of SEP-380135 in Adults With Schizophrenia or Major Depressive Episode | P1 | completed | 43 | Otsuka Pharmaceutical Development & Commercialization, Inc. | Nov 2024 | |
| NCT07305779 | A Trial to Test the Effects of Other Drugs on SEP-380135 in Healthy Men and Women | P1 | completed | 12 | Otsuka Pharmaceutical Development & Commercialization, Inc. | Mar 2025 |
SEP-380135 clinical trials: frequently asked questions
- How many SEP-380135 clinical trials are there?
- 3 SEP-380135 clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 2 are marked completed.
- Are SEP-380135 clinical trials recruiting in 2026?
- No active SEP-380135 trials are recruiting on ClinicalTrials.gov as of the current AACT refresh. Trials may resume; this page is updated daily.
- What conditions is SEP-380135 being studied for?
- SEP-380135 is being studied for Schizophrenia, Bipolar Disorder, Major Depressive Disorder (MDD). The trials are grouped by indication on this page.
- What phase is SEP-380135 in?
- SEP-380135 clinical trials span 3 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors SEP-380135 clinical trials?
- The lead sponsor across the most SEP-380135 trials is Otsuka Pharmaceutical Development & Commercialization, Inc.. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming SEP-380135as an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: